abstract |
The present technology is directed to composition that may be formulated for parenteral administration, where the composition includes a plurality of nanoparticles and optionally a pharmaceutically acceptable carrier. Each nanoparticle of the plurality includes a glatiramoid and one or more of a polyinosine-polycytidylic acid (Poly(I:C)), a plasmid DNA (pDNA), a CpG oligodeoxynucleotide (CpG ODN), or a combination of any two or more thereof. |